SNSE News and Press, Sensei Biotherapeutics Inc. From 05/20/21

Gainers: Precipio (PRPO) +23%, PDS Biotechnology (PDSB) +20%, Sensei Biotherapeutics (SNSE) +18%, Iovance Biotherapeutics (IOVA) +17%, Tyme Technologies (TYME) +12%.Losers: Black Diamond Therapeutics (BDTX) -30%, Aerpio Pharmaceuticals (A...

– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated – – One deep (71% tumor reduction) and durable (11 months) partial response and two longstanding (8 and 10 months) stable diseases observed in patients with no res...

Sensei Biotherapeutics (SNSE): Q1 GAAP EPS of -$0.42 misses by $0.09.Cash and cash equivalents of $169.4MPress Release For further details see: Sensei Biotherapeutics EPS misses by $0.09

- ImmunoPhage™ platform programs and the VISTA program continue to advance - - New safety and efficacy data from ongoing Phase 1/2 combination study of SNS-301 in squamous cell carcinoma of the head and neck accepted for presentation at ASCO 2021 - - Patient dosin...

BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a  clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointments of Maura Gillison, M.D....

Insider buying decreased significantly last week. Notable Insider Buys: HighPeak Energy, Inc., William Penn Bancorporation, Bioventus Inc., Athenex, Inc., Sensei Biotherapeutics, Inc. Notable Insider Sells: Facebook, Inc., Ulta Beauty, Inc., Guardant Health, Inc., Applied Material...

BOSTON and ROCKVILLE, Md., April 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Jessie M. English, Ph.D. ...

Sensei Biotherapeutics (SNSE): FY EPS of -$12.53 may not be comparable to consensus of -$1.00.Cash and cash equivalents of $16.6MPress Release For further details see: Sensei Biotherapeutics EPS of -$12.53

-Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds – -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in combination with pembrolizumab for the treatment of locally advanced unresectable or ...

BOSTON and ROCKVILLE, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it will be added to the Russell 2000&#x...